Clinical trials: Breast Tumor Tissue
Progression-free Survival
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who…
- Trial name
- NCT00944918
- Testing
- fulvestrant, anastrozole, exemestane
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Breast Cancer
Breast Study to Determine the Ability of Non-Invasive Optical Transillumination Spectroscopy to Predict Breast Density.
The purpose of this study is to learn more about the application of transillumination measurements in the determination of breast cancer risk.
- Trial name
- NCT00188682
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
ER-Positive HER2-Negative Breast Cancer
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone…
- Trial name
- SERENA-4 (NCT04711252)
- Testing
- AZD9833, Anastrozole, Palbociclib
- Where
- 263 sites in United States, Austria and 25 more
- Volunteers
- 1,371 people
- Sponsor
- AstraZeneca
Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma
CAIX-targeted PET/CT in Solid Tumors
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance.
- Conditions
- Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer
- Trial name
- CAIX-PET (NCT07833085)
- Testing
- 68Ga-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
- Trial name
- NCT00004125
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Liver Metastases
Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.
The goal of this observational study is to learn about breast cancer liver metastasis in patients who met the following criteria: female; be ≥ 18 years of age on the day of signing informed consent; confirmed diagnosis of breast…
- Trial name
- OLiver Pro (NCT05720676)
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Metastatic Breast Cancer
Fast-Her: Fasting Effects on Breast Cancer Treatment
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment.
- Trial name
- NCT07624617
- Testing
- Normal Eating, Prolonged Fasting
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Breast Cancer
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
This study is a multicenter, prospective, randomized phase II trial designed to observe and evaluate the efficacy and safety of trastuzumab, pertuzumab, docetaxel combined with QL1706 versus combined with carboplatin as…
- Trial name
- NCT07246317
- Testing
- QL1706 injection, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar)
- Where
- 8 sites in China
- Volunteers
- 188 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer, Tyrosine Kinase Mutation
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the…
- Conditions
- Cancer, Tyrosine Kinase Mutation, Breast Cancer, Melanoma
- Trial name
- LONGEVITI (NCT05645510)
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University of Alberta
Breast Cancer
Trial of Perioperative Endocrine Therapy - Individualising Care
To determine whether perioperative endocrine therapy with an aromatase inhibitor (AI) followed by standard adjuvant therapy improves outcome compared with standard adjuvant therapy alone in postmenopausal women with hormone…
- Trial name
- POETIC (NCT02338310)
- Testing
- Aromatase Inhibitors
- Where
- 128 sites in United Kingdom
- Volunteers
- 4,486 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make…
- Trial name
- NCT00004038
- Testing
- Ad5CMV-p53 gene, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Breast Cancer
A Prospective Comparative Study Between Oncoplastic Breast Surgery and Standard Wide Local Excision
The aim of this study is to asses the oncological safety of oncoplastic breast surgery, and its impact on patient satisfaction.
- Trial name
- NCT02923635
- Testing
- Standard wide local excision., oncoplastic breast surgery.
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Breast Cancer, Lung Cancer
Metabolic Changes as a Diagnostic Indicator for Cancer
This study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer.
- Trial name
- NCT02362776
- Testing
- Venous blood sample
- Where
- 2 sites in Belgium
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Hereditary Breast and Ovarian Cancer
Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
The hypothesis of this 3 year, prospective randomized multicenter efficacy trial is that a structured life-style intervention program with exercise training and mediterranean diet is effective regarding increased adherence to a…
- Trial name
- LIBRE-2 (NCT02516540)
- Testing
- Structured exercise training plus mediterranean diet
- Where
- 19 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Technical University of Munich
Breast Cancer, Breast Cancer Risk
Genetic Assessment of Breast Cancer Risk in Women in the DORA Programme
This prospective study evaluates whether a more detailed clinical and genetic assessment can improve the classification of individual breast cancer risk among women previously identified as having moderately increased or high…
- Trial name
- NCT07734389
- Testing
- Comprehensive Clinical and Genetic Breast Cancer Risk Assessment
- Where
- Slovenia
- Volunteers
- 291 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer Female
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2
The study should evaluate distribution of 99mTc-ZHER2:41071 Affibody molecule in patients with primary HER2-positive and HER2-negative breast cancer The primary objectives are: 1.
- Trial name
- NCT05203497
- Testing
- SPECT
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Breast Cancer
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
This study is being conducted to investigate the effect of a more in-depth education plan for patients with breast cancer. Patients will be randomized to receive either the standard education plan during their breast cancer…
- Trial name
- NCT02366806
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of California, Davis
HER2-positive Breast Cancer, Stage I Breast Cancer
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff…
- Trial name
- ELPIS (NCT04578106)
- Testing
- Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Fundacio Clinic Barcelona
Breast Cancer
VEGF Early Imaging for Breast Cancer
Breast cancer is the most common cause of cancer death among women. Yearly around 12,500 Dutch women are diagnosed with breast cancer and 3,500 die of this disease.
- Trial name
- NCT00991978
- Testing
- 89Zr-bevacizumab PET
- Where
- Netherlands
- Volunteers
- 23 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.